Senzime Valuation
Is 6YC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6YC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6YC (€0.47) is trading above our estimate of fair value (€0.15)
Significantly Below Fair Value: 6YC is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6YC?
Key metric: As 6YC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6YC's PS Ratio? | |
|---|---|
| PS Ratio | 11.8x |
| Sales | SEK 55.29m |
| Market Cap | SEK 655.08m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.4x |
| Enterprise Value/EBITDA | -4.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6YC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
PUS PULSION Medical Systems | 3.8x | n/a | €134.4m |
AAQ1 aap Implantate | 1.9x | n/a | €22.4m |
GME Geratherm Medical | 1.3x | 1.9% | €18.8m |
SBS Stratec | 1.5x | 7.7% | €334.9m |
6YC Senzime | 11.8x | 71.9% | €655.1m |
Price-To-Sales vs Peers: 6YC is expensive based on its Price-To-Sales Ratio (11.8x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does 6YC's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: 6YC is expensive based on its Price-To-Sales Ratio (11.8x) compared to the European Medical Equipment industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is 6YC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.8x |
| Fair PS Ratio | 8.6x |
Price-To-Sales vs Fair Ratio: 6YC is expensive based on its Price-To-Sales Ratio (11.8x) compared to the estimated Fair Price-To-Sales Ratio (8.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €1.06 0% | 2.0% | €1.08 | €1.04 | n/a | 2 |
| Nov ’25 | €0.50 | €1.06 +112.5% | 2.0% | €1.08 | €1.04 | n/a | 2 |
| Oct ’25 | €0.55 | €1.09 +97.9% | 2.0% | €1.11 | €1.06 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Sensus Healthcare
US$143.9m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$8.25
7D
4.4%
1Y
263.8%
Shandong Weigao Group Medical Polymer
HK$20.2b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.9%
1Y
-37.7%
LNA Santé
€240.3m
Engages in the management and operation of health establishments.
2N3
€23.00
7D
1.5%
1Y
17.7%